RECENT UPDATES - EVENTS

^05/07/2025

Daiichi Sankyo becomes “Golden Ticket” sponsor of the Bio^M biotech incubator MAxL

Founding teams can conduct research at MAxL free of charge for one year

The Japanese pharmaceutical company Daiichi Sankyo has become a “Golden Ticket” sponsor of the Bio^M incubator MAxL (Munich Accelerator Life Sciences & Medicine). Through this partnership, Daiichi Sankyo specifically supports emerging biotech start-ups thereby making an important contribution to promoting innovative therapeutic approaches in the biomedical field.

The incubator, managed by Bio^M, is specifically designed to support pre-seed and early-stage start-up teams in the life sciences and healthtech sectors. It is intended to facilitate the translation of scientific findings into market-ready products thereby filling an important gap in the start-up ecosystem.

MAxL's Golden Ticket program enables an outstanding founding team to advance its research work in the incubator's state-of-the-art laboratory and co-working space free of charge for one year. The team also benefits from... [read more]

With MAxL, we create the perfect conditions for successful start-ups.

MAxL is Bio^M's unique co-creation start-up incubator for the medicine of the future and life sciences in Martinsried/Munich, Europe's hotspot for biotechnology.

Would you also like to become part of MAxL? Then get in touch with us!

HOME OF PRE-SEED AND EARLY-STAGE TEAMS.

MAxL offers all you need to develop your ideas into market-ready products.

Based on Bio^M's strong and long-standing expertise, MAxL supports selected pre-seed and early-stage start-up teams from Bavaria and beyond with an exclusive high-end infrastructure: shared fully equipped lab space, co-working and community rooms, a structured incubation and coaching program as well as numerous networking opportunities.

Go to MAxL's portfolio of services.

We also offer partnerships with pharma, big biotech, deeptech and other industry players as well as strategic partners, CROs and investors.

Become a sponsor.

MAxL is the home of innovative pre-seed and early-stage start-up teams from Bavaria that aim at transforming medicine with their products and services.

News:

^{13/02/2025 | 17:00}

Cardior co-founder and RNA expert Prof. Thomas Thum joins board of MAxL team RNATICS

Biotech start-up RNATICS strengthens its management team with Prof. Dr. Thomas Thum. As an internationally recognized expert in the field of RNA medicine, he will provide the company with strategic and scientific support. RNATICS is part of BioM's MAxL start-up incubator and develops innovative RNA therapeutics against inflammatory lung diseases.

The Martinsried-based biotech start-up RNATICS has appointed Prof. Dr. Thomas Thum to its Board of Directors. With more than 20 years of experience in the field of RNA therapeutics and as co-founder of Cardior Pharmaceuticals GmbH, Thum has made a significant contribution to the development of innovative RNA-based approaches. In addition to his role as Director of the Institute for Molecular and Translational Therapeutic Strategies (IMTTS) at the... [mehr]

^{26/06/2024 | 08:00}

MAxL openingOn June 25, 2024, we inaugurated our start-up incubator MAxL together with State Secretary Tobias Gotthardt!

Around 120 invited guests from politics, science, industry and the investment sector celebrated the opening - also present: our first two tenants Leopard Biosciences and RNATICS.

MAxL opening (YouTube Video)

An dieser Stelle sind Inhalte vom externen Anbieter (https://www.youtube.com/) vorgesehen. Wir weisen darauf hin, dass die Inhalte und die Verarbeitung Ihrer Daten bei Klicken auf diesen Link außerhalb des Verantwortungsbereichs von bio-m.org liegen und möglicherweise nicht mehr dem Schutzbereich der Datenschutzgrundverordnung unterliegen. Es gelten ausschließlich die Datenschutzbestimmungen des Anbieters. Im Falle eines YouTube-Videos verweisen wir zusätzlich auf unsere Datenschutzerklärung.

The project is funded by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy with 8.5 million euros from 2023 to 2027 and is managed by the Bio^M cluster management company.